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The treatment of tuberculosis (TB) has witnessed
many important changes over the years. With the
advent of effective antimycobacterial
chemotherapeutic agents in the early 1950s, the two
main biological obstacles to successful treatment of
TB were the high rate of failure during treatment and
the high risk of relapse after treatment. The former
was due to the selection of drug resistant mutants of
Mycobacterium tuberculosis during the initial stages
of treatment when the bacterial populations in the
lesions were large. Relapse was due to the regrowth
of viable organisms that had persisted in the latent
state. To overcome these obstacles it was necessary
to give the patients a three-drug combination initially
and secondly to continue the treatment for 18 to 24
months with two drugs.
With the introduction of rifampicin the outlook
for treatment of TB changed dramatically. It was no
longer necessary to give streptomycin daily for three
months initially to prevent failure. The relapse rate
also came down steadily even though the duration of
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After treptomycin, which heralded the era of antibacterial chemotherapy for tuberculosis (TB),
many important advances have made available treatment regimens that are almost 100 per cent
curative. Randomised clinical trials by the Tuberculosis Research Centre, in Chennai and British
Medical Research Council in East Africa and in the Far East have helped to establish many of the
principles of antituberculosis chemotherapy. With successes have also come fresh challenges.
Mycobacterium tuberculosis becomes rapidly resistant to the drugs used against it and in the last
decade, the HIV epidemic has had an adverse impact on the global epidemiology of tuberculosis,
with many countries in Sub-Saharan Africa experiencing a 2-3 fold increase in their TB burden.
While the currently recommended treatment regimens are very effective, they have failed to control
the burden of  TB in the developing countries due to less than satisfactory implementation of the
control programmes. Faced with the dual threat of multidrug resistant TB and the HIV/facilitated
increase in TB, the WHO has instituted a Global TB Control Programme based on the directly
observed treatment shortcourse (DOTS) strategy. Much of the principles of this strategy have
come out of research in India. As part of this strategy, the Government of India is implementing
a Revised National Tuberculosis Control Programme (RNTCP). Under the RNTCP standardized
treatment regimens are prescribed for different treatment categories. Already more than 80 per
cent of the population is covered by this Programme and full coverage is slated for 2005.
Meanwhile, fresh research is ongoing to shorten treatment duration, a measure that should
greatly aid TB control.
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treatment was considerably shorter. This was possible
because complete, or almost complete sterilization
of the lesions became feasible with the introduction
of rifampicin and pyrazinamide.
Principles of treatment of tuberculosis
To understand the principles of the treatment of
TB it is necessary to study its evolution over the
years. For a disease that has been in existence since
antiquity and has left its imprint on the history of
mankind, specific treatment aimed at the causative
agent became available for the first time only in 1944
with the discovery of streptomycin by Selman
Waksman1,2. Before that time empirical measures
such as blood letting, horse riding, sea voyages,
graded exercise, absolute bed rest, calcium, injections
of extracts of gold or other heavy metals, artificial
pneumothorax or peritoneum, thoracoplasty, and
various other exotic remedies were practiced, usually
in the setting of a sanatorium, and without much
success3. Soon after the discovery of streptomycin,
para aminosalicylic acid (PAS) in 1949, and isoniazid
in 1952 became available, heralding the era of
effective antituberculosis chemotherapy. The main
objective of treatment of TB in the early years of
chemotherapy was to prevent the emergence of drug
resistance. This required treatment for a prolonged
duration of 18 to 24 months. The discovery of
rifampicin in the late 1960s and the rediscovery of
the antimycobacterial activity of pyrazinamide soon
after, were major breakthroughs in the treatment of
TB that made it feasible to shorten the duration of
treatment considerably. Randomised clinical trials
carried out by the British Medical Research Councils
(BMRC) in East Africa and Hong Kong and the
Tuberculosis Research Centre (TRC) of the Indian
Council of Medical Research in Chennai, India,
served to establish many of the principles of the
chemotherapy of TB4,5. The stage for these important
developments was set by the landmark clinical trial
by the TRC, Chennai (then called the Tuberculosis
Chemotherapy Centre) in the late 1950s showing that
TB could be treated effectively on an outpatient basis
and did not require admission in a sanatorium6. This
study not only established the bacteriological efficacy
of the treatment regimen in curing the patient, but
also showed that the close contacts of those patients
treated at home were not at a greater risk of
developing TB compared to the contacts of those
treated in the sanatorium7. The global impact of the
findings of this study is now well recognized and
domiciliary treatment for TB became the therapeutic
policy for developing countries8.
The first reports of effective short-course treatment
for TB came from East Africa9,10. In a randomized
clinical trial the efficacy of four 6-month regimens
(streptomycin and isoniazid, streptomycin, isoniazid
and rifampicin, streptomycin, isoniazid and
pyrazinamide, streptomycin, isoniazid and
thioacetazone) was compared with a standard 18-
month regimen of isoniazid and thioacetazone for the
treatment of patients with pulmonary TB. It was
found that the 3-drug combination of streptomycin,
isoniazid and rifampicin resulted in sputum
conversion in all the patients at the end of treatment
and a relapse rate of only 3 per cent. This study was
the forerunner of several other studies on short-course
chemotherapy in East Africa and other countries
including India, which helped to identify the specific
role of each drug in the multi-drug treatment regimen,
its role in the particular phase of treatment, to
establish dosage levels, to identify drugs suitable for
intermittent drug dosing, delineate ideal treatment
durations and document adverse reactions of
individual drugs and regimens5.
In addition to findings from clinical trials,
evidence from animal experiments at the Pasteur
Institute in Paris11, from in vivo and in vitro laboratory
work by Dickinson and  Mitchison in London12 and
from studies in East Africa on early bactericidal
activity13 have provided valuable data on the activity
of antituberculosis drugs. On the basis of these
findings, Mitchison suggested the existence of four
types of bacterial populations in a patient with TB,
according to their anatomical locations and degree
of metabolic activity14. The first is a population of
actively growing bacilli present in liquefied caseous
material of the tuberculous lesion and the lining of
the walls of pulmonary cavities. This is by far the
largest fraction of the total bacterial population and
contributes to the entire bulk of the bacilli excreted
in the sputum. These bacilli are killed by isoniazid,
and to a lesser extent by rifampicin and streptomycin.
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The second population consists of slow-growing
bacilli situated within macrophages in an acid milieu;
pyrazinamide is the only drug that acts on this
population, and probably rifampicin, to a lesser
extent. The third population consists of small number
of bacilli present extracellularly in solid caseous
lesions and exhibit brief spurts of growth; rifampicin
is the only drug that acts rapidly and kills these bacilli
during their brief periods of activity. Besides these
three populations of bacilli there probably exists a
fourth population of dormant bacilli that is beyond
the reach of any drug. All these populations of bacilli
exist in the lesions and therefore it is necessary to
give at least 3 drugs, isoniazid, rifampicin and
pyrazinmide, and possibly streptomycin as well to
cover the spectrum of all the bacillary populations,
to ensure sterilization of the lesions.
Drug combinations in short course chemotherapy
Short-course chemotherapy has been the standard
of care for treating TB for the last 30 years. The choice
of the individual drugs in the treatment regimen in
short-course chemotherapy is crucial. Bactericidal and
sterilizing activities of the individual drugs have to be
considered. Evidence of bactericidal activity can be
obtained from laboratory studies on the effects of the
drugs on cultures of tubercle bacilli in vitro, efficacy
of the drugs in experimental TB in laboratory animals
and the speed of sputum conversion in patients
undergoing treatment and the magnitude of the fall in
the bacterial content of sputum within a short period
of initiation of treatment15. The sterilizing activity of
the drugs is assessed from the proportion of patients
who have bacteriological relapse after stopping
treatment. The bactericidal activity of antituberculosis
drugs as assessed in in vitro and animal experiments
is shown in Table I.
Current short-course regimens use an initial
intensive phase (usually 2 months) of multiple drugs
to rapidly reduce the number of organisms present;
this is followed by a longer continuation phase of
fewer drugs that have the ability to kill (sterilize) the
more slowly growing organisms. From studies done
in human treatment trials, the rate of killing appears
to be fastest during the initial several days of
treatment13. Thus, the first phase of antituberculosis
treatment focuses on rapid killing of organisms and
is referred to as the phase of bactericidal activity.
The measure of bactericidal activity of a treatment
regimen is the proportion of patients who become
sputum culture negative after two months of
treatment. Fig. 1 summarises the bactericidal activity
of different antituberculosis drugs assessed by the
proportion of patients who become sputum culture
negative after two months of treatment, in patients
with bacteriologically positive pulmonary TB treated
in clinical trials in Madras16, East Africa17 and Hong
Kong18. Isoniazid alone produced sputum culture
conversion in 44 per cent of patients, reflecting its
high bactericidal potential. The addition of a
bacteriostatic drug thioacetazone, or PAS or
ethambutol to isoniazid did not result in any
significant increase in culture negativity. Even the
addition of a bactericidal drug streptomycin to
isoniazid only resulted in a marginal increase to
49 per cent. In contrast, the addition of pyrazinamide
or rifampicin contributes significantly to the
bactericidal activity and are therefore suitable for
short-course chemotherapy.
In contrast, it takes a much longer time to kill the
more slowly growing organisms or persistors, and the
goal of this phase of treatment is to kill all the
remaining viable bacilli or reach a point of
sterilization; thus, the second phase of treatment is
referred to as the phase of sterilizing activity. The
measure of the sterilizing activity of a regimen is
reflected by the relapse rate after successful treatment.
Table I. Bactericidal activity of first line antituberculosis drugs
in in vitro studies and in animal experiments
Drug Bactericidal activity
In vitro In mouse In guinea pig
Isoniazid 2+ 2+ 2+
Rifampicin 2+ 2+ 2+
Streptomycin 3+ 1+** 2+
Pyrazinamide 2+* 2+** 0**
*pH 5.2-5.6
** Drugs given in dosage considerably higher than that used
in man
0, no activity
1+, 2+,  3+ (indicate increasing degrees of bacterial activity)
Source: Ref. 15
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Of these two phases, it is the sterilizing activity
of a regimen that is more important because it
determines the duration of treatment; the better the
sterilizing activity of a regimen, shorter the duration
of treatment. In contrast, the early bactericidal activity
of an antituberculosis regimen is less important
overall except it probably provides an indication of
how long a patient remains infectious. Fig.2
illustrates the sterilizing activities of different drug
combinations in clinical trials for the treatment of
patients with bacteriologically positive pulmonary TB
in East Africa10,19 and Hong Kong18,20. The addition
of thioacetazone to streptomycin-isoniazid
combination did not contribute to the sterilizing
activity with the relapse rate continuing to be high,
viz., 22 per cent. Pyrazinamide, on the other hand
made a significant contribution and reduced the
relapse rate from 29 to 8 per cent. It is also seen that
the sterilizing activity of ethambutol is inferior to
that of pyrazinamide. The low rate of relapses with
the 6-month isoniazid-rifampicin and the 6-month
isoniazid-rifampicin-streptomycin regimens are
Fig.1. Bactericidal activity of different antituberculosis drugs assessed by the proportion of patients who become sputum culture
negative after two months of treatment, in patients with bacteriologically positive pulmonary tuberculosis treated in clinical trials
in Madras, East Africa and Hong Kong.
H, isoniazid; T, thioacetazone; P, para-aminosalicylic acid (PAS); E, ethambutol; S, streptomycin; Z, pyrazinamide; R, rifampicin
Source: Refs.16-18.
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reflective of the substantial and significant
contribution of rifampicin in achieving sterilisation.
Intermittent treatment regimens
The efficacy of intermittent treatment (i.e.,
treatment given twice or thrice-weekly rather than
daily) was established fairly early in the history of
the chemotherapy of TB. Intermittent treatment is
based on the lag effects exhibited by cultures of M.
tuberculosis  after being exposed to pulses of
bactericidal antituberculosis drugs such as isoniazid
and rifampicin, but not to a bacteriostatic drug such
as thioacetazone, and in experimental tuberculosis
in guinea pigs21-23. A randomized clinical trial by the
TRC, Chennai, showed that streptomycin plus
isoniazid twice a week for 12 months was as effective
in providing a bacteriological cure as PAS and
isoniazid given daily for 12 months in patients with
sputum positive pulmonary TB24,25. A BMRC study
in Hong Kong showed that streptomycin, isoniazid
and pyrzinamide given for 9 months either daily, or
thrice-weekly or twice-weekly were all equally
efficacious26. Subsequently another study from the
same site showed that 6 months of a thrice-weekly,
4-drug regimen was very effective so long as
isoniazid, rifampicin and pyrazinamide were included
in the regimen; substituting ethambutol for
pyrazinamide however increased the relapse rate to
an unacceptably high level27 (Table II).
A large randomized clinical trial in Chennai by
the TRC28 compared either thrice-weekly or twice-
weekly 4-drug regimens (isoniazid, rifampicin,
pyrazinamide and streptomycin) for the first two
months followed by either twice-weekly or once-
weekly 3-drug or 2-drug combinations for the next 4
months. The second month sputum culture negativity
ranged from 86 to 89 per cent and the relapse rates
were 3 per cent for the thrice-weekly initial phase
Fig.2. Relapse rates of different drug combinations in clinical trials for the treatment of patients with bacteriologically positive
pulmonary tuberculosis East Africa and Hong Kong.
S, streptomycin; H, isoniazid; T, thioacetazone; Z, pyrazinamide; R, rifampicin; E, ethambutol; tw, indicates treatment given
twice-weekly
Numbers preceding drug regimens indicates number of months of treatment
Source: Refs.10, 18-20.
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regimens and 6 per cent for the twice-weekly initial
phase regimens, respectively.
The advantages of intermittent treatment are
significant. While the efficacy is equal to that of daily
treatment, intermittent regimens are less expensive,
have fewer adverse drug reactions and most
importantly, intermittent treatment facilitates directly
observed therapy. Poor adherence to treatment by
patients has been, and still is, the biggest bugbear
for control of TB, as many patients discontinue
treatment before completing the full course. So, the
establishment of intermittent treatment was a major
breakthrough in TB treatment.
Tuberculosis control
The treatment of patients with active TB is the
cornerstone of any TB control programme. The
World Health Organisation’s (WHO) Global
Tuberculosis  Programme emphasises  the
importance of standardised treatment administered
under direct observation as one of the important
components of its global strategy to control TB.
The ‘directly observed treatment short course’
(DOTS) strategy, is today recognised as the only
means by which effective TB control could be
achieved. From the public health perspective the
highest priority in a TB control programme is the
identification and treatment of the infectious TB
patient, i.e., those patients with sputum smear-
positive pulmonary TB. In settings of resource
constraints it is necessary for rational resource
allocation to prioritise TB treatment categories
according to the cost-effectiveness of treatment of
each category. The WHO has ranked TB patients
from category I (highest priority) to category IV
(lowest priority) and the treatment regimen for
each category is shown in Table III29. Disease
categorisation is based on the severity of the
disease judged by the patient’s sputum smear
status and or clinical condition and radiological
extent of the disease, the site of the disease
(pulmonary or extra-pulmonary) and whether or
not the patient had received prior treatment for
TB.  Signif icant  modif icat ions  in  the  WHO
guidelines of 200329 from the previous guidelines
of 199730 are (i) TB patients with concomitant HIV
infection are included in category I; and (ii) the
treatment for category III patients is the same as
that for category I patients, i.e., a 4-drug intensive
phase followed by a 2-drug continuation phase.
Member countries have the liberty to choose the
regimens most appropriate for them.
Table II. Rates of relapse after treatment in patients treated with daily and intermittent regimens in Hong Kong
Study Regimen Patients % relapse
Hong Kong Chest 9 SHZ 65 5*
Service/BMRC26 9 SHZ thrice-weekly 65 6*
9 SHZ twice-weekly 49 6*
Hong Kong Chest 6 HRZE 161 1**
Service/BMRC27 6 HRSZE thrice-weekly 150 1**
6 HRSZ thrice-weekly 150 1**
6 HRSE thrice-weekly 160 8**
6 HRZE thrice-weekly 161 2**
BMRC, British Medical Research Councils
Superscript numerals represent reference numbers
Number preceding regimens indicates months of treatment
S, streptomycin; H, isoniazid; Z, pyrazinamide; R, rifampicin; E, ethambutol
* relapse rates at 30 months
** relapse rates at 12 months after
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Revised National Tuberculosis Control
Programme (RNTCP)
India has had a National Tuberculosis Control
Programme functioning from the early 1960s. This
programme was based on the research findings of the
TRC and the National Tuberculosis Institute (NTI)
in Bangalore. Though the programme was based on
sound epidemiological and scientific principles, a
comprehensive review of the programme in 1992
identified that it suffered from managerial weakness,
inadequate funding, over-reliance on X-ray for
diagnosis, non-standard treatment regimens, low rates
of treatment completion and lack of systematic
information on treatment outcomes31.  Faced with
these facts the Government of India has implemented
a Revised National Tuberculosis Control Programme
(RNTCP). This programme builds on the substantial
infrastructure established by the previous programme.
The RNTCP is based on the WHO’s DOTS strategy
Table III. WHO recommended treatment regimens for different disease categories
Disease Tuberculosis patient definition Treatment regimen
Category
Initial phase Continuation
(daily or three phase
times weekly) (daily or three
times weekly)
I New smear-positive
New smear-negative with
extensive parenchymal 2 HRZE* 4 HR or
involvement 6 HE daily
New severe extra-pulmonary
tuberculosis or severe
concomitant HIV infection
II Previously treated sputum
smear-positive pulmonary
tuberculosis 2 HRZES/ 5 HRE
- relapse 1 HRZE
- treatment after interruption
- treatment failure
III New smear-negative 4 HR or
pulmonary tuberculosis 2 HRZE 6 HE daily
Extra-pulmonary tuberculosis
IV Chronic and MDR Specially designed
tuberculosis standardized or
individualized regimens
H, isoniazid; R, rifampicin; Z, pyrazinamide; E, ethambutol; S, streptomycin
* Streptomycin may be used instead of ethambutol. In meningeal TB ethambutol should be replaced by streptomycin.
MDR – multidrug resistant
Number preceding regimens indicates months of treatment
Source: Ref. 29
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and consists of the following components: (i)
diagnosis of pulmonary TB to be made primarily by
sputum microscopy; (ii) treatment to be given under
direct observation, at least during the intensive phase;
(iii) regular drug supply to be ensured; (iv) the
patient’s progress to cure to be monitored by follow-
up sputum tests; and (v) ensuring administrative and
political commitment. Treatment is given thrice-
weekly both during the intensive phase and the
continuation phase32 (Table IV). Category I patients
are those with newly diagnosed smear-positive
pulmonary TB, or newly diagnosed smear-negative
pulmonary TB who are clinically seriously ill or with
extensive parenchymal lesions on the chest X-ray,
or those with severe forms of extra-pulmonary TB.
Category II patients are those with sputum smear-
positive pulmonary TB who have been treated for
TB in the past, and who have now presented with a
relapse, or treatment failure or have attended after a
period of interrupted treatment. Category III patients
consist of newly diagnosed sputum smear-negative
pulmonary TB and those with non-serious forms of
extra-pulmonary TB, viz., TB of the lymphnodes, skin
or unilateral pleural effusion.
Category I patients receive a 6-month regimen
consisting of isoniazid, rifampicin, pyrazinamide and
ethambutol thrice-weekly for two months followed
by isoniazid and rifampicin thrice-weekly for four
months (2HRZE thrice-weekly/4HR thrice-weekly).
The patient’s response to treatment is monitored with
sputum smear examinations at 2 and 4 months and at
Table IV : Recommended treatment regimens for different disease categories under Revised National Tuberculosis Control
Programme of India
Disease Tuberculosis patient definition Treatment regimen
category
Initial phase Continuation phase
I New smear-positive
New smear-negative with
extensive parenchymal 2 HRZE 4 HR
involvement thrice-weekly thrice-weekly
New severe extra-pulmonary
tuberculosis
II Previously treated sputum
smear-positive pulmonary
tuberculosis 2 HRZES/ 5 HRE
- relapse 1 HRZE thrice-weekly
- treatment after interruption thrice-weekly
- treatment failure
III New smear-negative 2 HRZ 4 HR
pulmonary tuberculosis thrice-weekly thrice-weekly
Extra-pulmonary tuberculosis
H, isoniazid; R, rifampicin; Z, pyrazinamide; E, ethambutol; S, streptomycin
Drug dosages in mg.: Thrice-weekly
Isoniazid 600
Rifampicin* 450
Ethambutol 1200
Pyrazinamide 1500
Streptomycin 750
* Rifampicin dosage 600 mg. For patients weighing 60 kg., or more
Source: Ref. 32
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the end of treatment. If the second month sputum
smear is positive the intensive phase is extended for
one more month.
Category II patients receive an 8-month regimen
consisting of isoniazid, rifampicin, pyrazinamide and
ethambutol thrice-weekly for three months with
streptomycin for the first two months, followed by
isoniazid, rifampicin and ethambutol thrice-weekly
for five months (2SHRZE thrice-weekly/1HRZE
thrice-weekly/5HRE thrice-weekly). As for category
I patients, sputum smear examination is done at the
end of the intensive phase, and if it is positive, the
intensive phase is extended by one more month.
Category III patients receive a 6-month regimen
similar to the category I regimen, but without
ethambutol in the intensive phase (2HRZ thrice-
weekly/4HR thrice-weekly).
During the intensive phase of treatment every dose
is administered under direct observation, while during
the continuation phase patients are asked to attend
the treatment clinic once a week, when one dose of
treatment is given under direct observation and the
other two doses given to the patient for self-
administration. A unique feature of the RNTCP is
that all the medicines come in blister packs and each
patient is allotted a box of medicines that contains
drugs for the full duration of treatment, at treatment
initiation. The drug box however will not be handed
over to the patient, but maintained in the treatment
clinic, and medicines from the box can be given only
to the allocated patient. This helps instill confidence
in the patient that he will never arrive at the treatment
centre and find that there are no medicines. Patients
who fail on category II regimen, some of whom are
likely to have multidrug resistance (MDR) should
be managed in specialised referral institutes.
How short is short-course chemotherapy?
In the last few years the fluoroquinolone group of
drugs have added a new dimension to the
chemotherapy of TB. Quinolones have considerable
in vitro activity against M. tuberculosis and other
mycobacteria33, and they have been used as part of
regimens to treat patients with MDR TB (TB caused
by M.tuberculosis that is resistant to isoniazid and
rifampicin with or without resistance to other anti-
TB drugs). There is limited data on the use of
fluoroquinolones in the treatment of patients with
drug-susceptible TB. A randomized trial first shed
light on the role of ciprofloxacin in the treatment of
drug- susceptible pulmonary TB34. A regimen of
isoniazid and rifampicin for 6 months plus
ciprofloxacin for the first 4 months was compared
with isoniazid and rifampicin for 6 months plus
pyrazinamide for the first 4 months plus ethambutol
for the first 2 months in HIV seropositive and
negative pulmonary TB patients. The relapse rate 6
months after treatment was unacceptably high with
the ciprofloxacin-containing regimen, indicating that
ciprofloxacin added nothing to the sterilizing activity
of isoniazid and rifampicin. However, a recent
landmark clinical trial from the TRC, Chennai studied
the role of ofloxacin in shortening the duration of
treatment for TB35.
One of the long-term goals for the control TB
has been to shorten the duration of treatment while
ensuring high rates of cure and low rates of relapse.
Shorter treatment regimens would ease drug
administration for both patients and providers. An
effective, fully oral regimen of 3 or 4 months’
durat ion would have s ignif icant  pract ical
advantages  for  TB control .   In  a  previous
randomized clinical trial by the TRC, Chennai, a
3-month regimen of daily streptomycin, isoniazid,
rifampicin, and pyrazinamide resulted in a nearly
100 per cent favourable outcome at the end of
treatment; yet 20 per cent of the patients relapsed
in the subsequent 21 months36. Based on that
experience, as well as the results of in vitro studies
demonstra t ing the  bacter ic idal  ac t iv i ty  of
ofloxacin37, the TRC conducted a randomized
clinical trial to assess the efficacy of 3-, 4-, and
5-month regimens using ofloxacin instead of
ethambutol in the intensive phase for the treatment
of patients with bacteriologically confirmed
pulmonary TB 35. The results in patients followed
up for 24 months after treatment showed that
among patients with drug-susceptible bacilli
treated with the 4- and 5-month regimens with a
3-month intensive phase of isoniazid, rifampicin,
pyrazinamide and ofloxacin daily followed by
407
isoniazid and rifampicin twice-weekly for one or
two months, only 4 and 2 per cent relapsed,
respectively. The sputum culture conversion after
2 months of treatment was 92-97 per cent. (Fig.3).
This study showed that it is feasible to shorten
the duration of treatment for smear-positive
pulmonary TB from the currently recommended 6
months to 4 months. With newer fluoroquinolones
such as moxifloxacin and gatifloxacin that exhibit
even more potent antimycobacterial activity, both
bactericidal38, and sterilizing39,40, it should be
possible in the near future to further reduce the
duration of treatment for TB. Clinical trials using
moxifloxacin or gatifloxacin along with first line
antituberculosis drugs are being planned at TRC.
Extra-pulmonary tuberculosis
Extra-pulmonary TB accounts for 10-15 per cent
of all cases of TB. In general it is more difficult to
diagnose than pulmonary disease, and often requires
invasive procedures to obtain diagnostic specimens
for histological or bacteriological confirmation.
Because this form of TB is not considered to be of
public health importance as the patients are not
infectious and do not transmit the disease to others,
Fig.3. Results in bacteriologically positive pulmonary tuberculosis patients treated with ofloxacin-containing regimens of 3,4
and 5 months in Chennai, South India.
Regimens:
30HRZ: ofloxacin, isoniazid, rifampicin and pyrazinamide daily for 3 months
30HRZ/1HRtw: oflaxacin, isoniazid, rifampicin and pyrazinamide daily for 3 months followed by isoniazid and rifampicin
twice-weekly for 1 month
30HRZ/2HRtw: oflaxacin, isoniazid, rifampicin and pyrazinamide daily for 3 months followed by isoniazid and rifampicin
twice-weekly for 2 month
20HRZ/2HRtw: oflaxacin, isoniazid, rifampicin and pyrazinamide daily for 2 months followed by isoniazid and rifampicin
twice-weekly for 2 month
Replapse rates are for 24 months after completing treatment.
Source: Ref. 35.
JAWAHAR : CHEMOTHERAPY OF TB
408 INDIAN J MED RES, OCTOBER 2004
most guidelines for treatment intended for use in low-
income countries have not addressed the treatment of
this entity in any great detail.
However, the TRC, Chennai has conducted clinical
trials in tuberculous lymphadenitis41,42, tuberculous
meningitis43, spinal TB 44,45,  abdominal TB 46,
tuberculoma of the brain47 and cutaneous TB
(manuscript in preparation). A BMRC study
investigated the efficacy of a 6-month regimen with
or without prednisolone for treating patients with
tuberculous pericarditis, in Transkei, South Africa48.
The evidence from all these trials indicate that extra-
pulmonary TB can be effectively treated with short-
course chemotherapy, often with fewer drugs than in
the case of pulmonary TB. Except for meningitis, all
other forms of extra-pulmonary TB can be
successfully treated with 6-month regimens. The
RNTCP recommends category III regimen for
lymphnode TB, cutaneous TB and unilateral pleural
effusion, and category I regimen for more severe forms
of extra-pulmonary TB. Patients with tuberculous
meningitis should be treated for at least nine months.
Corticosteroids should be used concurrently, at least
in the initial stages of treatment for meningitis,
pericarditis and large pleural effusions.
Tuberculosis in children
The DOTS strategy is applicable to all patients
with TB, including children. The recommended
regimens for the treatment of childhood tuberculosis
are the same as for adults. The dosage of drugs is
shown in Table V. However, there are important
differences between children and adults that may affect
drug choice and dosage, which need to be borne in
mind. Recommended dosage is based on research in
adults and yet metabolism of drugs varies with age.
The effectiveness of an ethambutol-isoniazid
continuation phase has never been studied in children,
whereas rifampicin-isoniazid has proved efficacy. In
children with tuberculous meningitis streptomycin
should be used instead of ethambutol because
ethambutol does not cross the blood-brain barrier.
Corticosteroids should also be used. Given the choice,
ethambutol should be avoided in young children, as it
will not be possible to monitor visual problems, if they
arise.
Child contacts of patients with infectious
tuberculosis
Children who are close household contacts of
sputum smear-positive pulmonary TB patients
should be screened for TB. Those with a diagnosis
of TB should be treated. Those who are well and
aged five years or less should receive isoniazid
prophylaxis (5 mg/kg daily) for three months. A
tuberculin test should be done then, if available. If
the test is negative BCG vaccination should be
given; if the tuberculin test is positive, isoniazid
prophylaxis should be continued for three more
Table V. Recommended drug dosage of antituberculosis drugs for childhood tuberculosis
Drug Recommended dosage (dose range) in mg/kg body weight
Daily Thrice-weekly
Isoniazid 5 10
(4-6) (8-12)
Rifampicin 10 10
(8-12) (8-12)
Pyrazinamide 25 35
(20-30) (30-40)
Streptomycin 15 15
(12-18) (12-18)
Ethambutol 15 30
(15-20) (20-35)
Thioacetazone 2.5 Not applicable
Source: Ref. 29
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months. If tuberculin test is not available, isoniazid
prophylaxis should be continued for six months.
Children who are well and above five years should
be clinically followed up49.
Multi-drug resistant tuberculosis (MDR TB)
The WHO declared TB as a global emergency in
1993. One of the reasons for this unprecedented
declaration was an epidemic of MDR TB in the USA
in the late 1980s and early 1990s, predominantly in
HIV infected individuals housed in prisons and shelters
for the homeless, conditions that facilitated rapid
transmission of infection. Mortality was in the order
of 80 per cent and the mean duration from diagnosis
to death was 4-16 wk50,51. Alarmed by this, the WHO
conducted a worldwide survey on drug resistance that
suggested that there were hotspots of MDR TB52. In
India initial resistance to rifampicin and isoniazid
ranged from 0.5 to 5.3 per cent53.
The importance of MDR TB lies in its poor
response to available therapeutic regimens. In HIV-
negative patients with MDR TB, only 56-88 per cent
show a consistent response to treatment and the risk
of failure is 80 times higher than in those with drug-
susceptible strains54. In a study on immunocompetent
MDR TB patients, the mortality directly attributable
to TB was 22 per cent55 while the mortality in HIV
infected patients has been reported to range from 75-
90 per cent56.
The management of MDR TB is a challenging
problem. Treatment is less effective, more toxic and
much more expensive compared to the treatment of
patients with drug susceptible TB. Certain guidelines
have to be borne in mind when confronted with
suspected drug resistance. The first and foremost of
these is to obtain from the patient an exhaustive and
meticulous history of previous treatment for TB.
Details such as the names of drugs, the dosage, when
taken, for what duration and with what regularity are
all important.  All available prescriptions have to be
scrutinised. Patients often do not know what drugs
they had been prescribed. So indirect questions might
be necessary, such as did the patient take any capsules
which made the urine red, any medicines that caused
joint pains etc.57. The treatment regimen should include
at least four drugs that the patient is known to be
susceptible to, or has not previously received,
Table VI. Regimens recommended by WHO for treatment of multidrug resistant tuberculosis (MDR TB)
Drug susceptibility profile Initial phase Continuation phase
of essential drugs: (6 months) (12-18 months)
Not available Kanamycin* Ethionamide
Ethionamide Quinolone
Quinolone** Pyrazinamide/ Ethambutol
Pyrazinamide/ Ethambutol
Resistant to Isoniazid and Streptomycin^ Ethionamide
rifampicin Ethionamide Quinolone
Quinolone Pyrazinamide/ Ethambutol
Pyrazinamide/ Ethambutol
Resistant to all essential 1 injectable + 1 quinolone 1 quinolone + 2 of these 3
drugs + 2 of these 3 drugs: PAS, drugs: PAS, Ethionamide,
Ethionamide, Cycloserine Cycloserine
Drug susceptibility profile Individually tailored regimen Individually tailored regimen
of reserve drugs available according to susceptibility pattern according to susceptibility pattern
*  Amikacin or capreomycin can also be used. However, since there is cross-resistance between kanamycin and amikacin, if either
drug was used previously, or if resistance to them is suspected, capreomycin is the preferred choice.
** Ofloxacin or ciprofloxacin
^  If resistance to streptomycin is confirmed, replace with kanamycin, amikacin or capreomycin
Source: Ref. 29
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Table VII. Symptom-based approach to side effects of antituberculosis drugs:
Side-effects Drugs(s) probably responsible Management
Minor:
Anorexia, nausea, Pyrazinamide, Continue anti-tuberculosis drugs
abdominal pain Rifampicin Check drug doses
Antacids, anti-emetics
Give drugs with small meals or
last thing at night
Itching, no rash Pyrazinamide Antihistamines
Rifampicin
Isoniazid
Streptomycin
Joint pains Pyrazinamide Aspirin
Burning sensation in feet Isoniazid Pyridoxine 100 mg
Major:
Giddiness or deafness Streptomycin Stop responsible drug(s)
Stop streptomycin; use
ethambutol
Jaundice, hepatitis Pyrazinamide, Stop pyrazinamide, rifampicin,
Rifampicin, isoniazid;
Isoniazid use streptomycin, ethambutol
Visual impairment Ethambutol Stop ethambutol
Pruritis, skin rash Thioacetazone Stop responsible drug
Pyrazinamide
Rifampicin
Isoniazid
Streptomycin
Shock, purpura, Rifampicin Stop rifampicin; never use
acute renal failure again
‘Flu syndrome’ Rifampicin Stop rifampicin
Seizures Isoniazid Stop isoniazid
Source: Ref. 29
including an injectable agent and a fluoroquinolone
in the initial phase, and at least three of the most active
and best tolerated drugs in the continuation phase.
Treatment should be given daily and directly observed.
An initial phase of at least six months should be
followed by a continuation phase of 12-18 months.
Treatment should be continued till the sputum cultures
remain negative for at least 12 months. Table VI lists
the regimens recommended by the WHO for treatment
of MDR TB29.
While drug susceptibility testing may not be
available in many resource-limited settings, all efforts
should be made to obtain a reliable drug susceptibility
profile of the patient’s infecting organisms. It is wise
to bear in mind that even in developed countries, there
is much variation in results from different laboratories
which perform drug susceptibility tests for M.
tuberculosis. Out of more than 80 strains of M.
tuberculosis typed as resistant to streptomycin,
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isoniazid or PAS at the peripheral laboratory, only
27-49 per cent of the strains were confirmed to be
resistant when retested at the reference laboratory58.
Incorrect susceptibility test results can lead to
unnecessary changes of regimen, decreasing the
chances of cure. Judicial clinical judgment often
obviates the need for drug susceptibility testing. If
drug susceptibility testing is considered essential, it
should be done in a laboratory with established
credentials.
An important dictum in the management of
tuberculosis is never to substitute a single drug in a
regimen that appears to be failing.  Doing so may
lead to the sequential development of resistance to
the drug that is being introduced. Always two or more
new drugs should be added to an existing regimen.
Since most drugs used in the treatment of MDR TB
have adverse effects, toxicity has to be carefully
monitored.  Sometimes drugs may need to be
withdrawn either temporarily or permanently and
alternate drugs substituted. Often adverse reactions
can be managed with symptomatic treatment. The
patient needs constant encouragement and motivation
to cope with adverse reactions to drugs and to
complete the full course of treatment. Ideally this
should be done in hospital and so it is a good policy
to hospitalise patients, at least initially, to facilitate
close monitoring, both for toxicity and for treatment
compliance.
The value of the older drugs in the treatment of
MDR TB today has to be emphasised.  Many young
patients with MDR TB have not received PAS or
thioacetazone in the past and these can be used with
success in such patients. So also the value of high
dose isoniazid (600 mg), in patients with documented
isoniazid resistance. In our experience at TRC,
Chennai, patients with MDR TB who have remained
sputum positive for years together when treated with
other drugs have converted to sputum negativity when
switched on to 600 mg of isoniazid and PAS as a last
resort.
The duration of therapy for MDR TB has not been
clearly established. The duration that has been
recommended in the USA is 18-24 months at least, or
for 24 months after sputum culture converts to
negative59. At the TRC, Chennai, MDR TB patients
are treated for a minimum period of 18 months and
for at least 12 months after sputum cultures become
consistently negative.
Role of Surgery
In carefully selected patients surgery may have an
important role to play in the management of MDR
TB. A number of studies have demonstrated the value
of resectional surgery in patients with predominantly
unilateral disease, with adequate respiratory reserve
and in whom chemotherapy alone had failed60,61.
Adverse reactions to anti-tuberculosis treatment
The currently recommended antituberculosis
regimens are usually well tolerated. However some
patients may experience problems, usually due to the
bulk of the drugs, a single day’s dose consisting of 6-
7 tablets. The patients have to be informed about the
orange discolouration of the urine due to rifampicin,
as this usually alarms patients if they are not told.
They have to be reassured that this is not something
unexpected or harmful.
Drug related adverse effects may be minor or
major29 (Table VII). In general, a patient who has
minor adverse effects should be encouraged to continue
the treatment with symptomatic measures such as
antacids, antihistamines, antiemetics or analgesics, as
indicated. If major adverse reactions occur, the
regimen, or the offending drug, if identified, must be
stopped. Further management depends on the nature
of the adverse reaction, and may have to be done in a
hospital.
Hepatic dysfunction:
Transient elevation of transaminase levels is
relatively common during the course of
antituberculosis treatment and does not warrant
interruption of treatment. Drug-induced hepatitis
accompanied by clinical jaundice necessitates
withholding of all drugs and institution of supportive
treatment. Once liver function returns to normal,
antituberculosis drugs may be reintroduced. If
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jaundice recurs, rifampicin, isoniazid and
pyrazinamide should be withdrawn and the patient
treated with streptomycin and ethambutol. During the
course of jaundice, if antituberculosis treatment is
considered essential, streptomycin and ethambutol
should be used.
Renal impairment: Rifampicin induced renal
impairment or failure is rare and is more common
when rifampicin is given intermittently62. It is believed
to be immune-mediated. Rifampicin should be stopped
immediately and measures to support renal function,
including heamodialysis, should be instituted. After
renal function returns to normal tuberculosis treatment
can be continued without rifampicin. Renal
impairment may also occur with streptomycin. In the
presence of pre-existing renal impairment rifampicin,
isoniazid and pyrazinamide can be given in normal
dosages. In the presence of severe renal failure dosage
of isoniazid should be reduced to 200 mg with
pyridoxine to avoid peripheral neuropathy.
Streptomycin and ethambutol are the two main drugs
that are cleared by the renal route. Extra care should
be exercised if these drugs are to be used in the
presence of renal impairment. Treatment should be
planned in consultation with the nephrologist.
Acute thrombocytopaenia and ‘shock syndrome’:
These are rare but life-threatening reactions that may
be caused by rifampicin. Rifampicin should be
immediately withdrawn from the treatment regimen
and supportive measures instituted. Rifampicin should
never be re-administered to such patients.
Flu syndrome: This is an immune mediated adverse
reaction attributed to rifampicin, usually when the
drug is administered in an intermittent rhythm and
rarely during daily therapy. It is characterized by fever
with or without chills, myalgia, headache and
prostration, which characteristically come on after a
defined time interval following rifampicin intake. It
can be managed with antipyretics, but if the symptoms
are severe, rifampicin should be withdrawn from the
treatment regimen.
Treatment of TB in special situations
Pregnancy: All first line antituberculosis drugs, except
streptomycin can be used in pregnancy. Pyridoxine is
sometimes recommended for pregnant women
receiving isoniazid. A pregnant woman should be
advised that successful treatment of TB with the
recommended regimens is important for successful
outcome of pregnancy. Women patients should be
advised to avoid pregnancy while on antituberculosis
treatment. Rifampicin interacts with oral contraceptive
medicines resulting in reduced protection against
pregnancy. A woman on oral contraceptives can
choose between two options while on treatment with
a rifampicin-containing regimen; she can either take
an oral contraceptive with a higher dose of oestrogen
(50: g) or adopt another form of contraception till TB
treatment is completed29.
Breast feeding women with TB should receive a full
course of antituberculosis treatment. All antituberculosis
drugs are compatible with breast feeding. The only
precaution that the mother should practice is not to cough
onto her baby. The baby should receive prophylactic
isoniazid for at least 3 months beyond the time the
mother is considered to be non-infectious. BCG
vaccination of the newborn should be postponed until
the end of isoniazid prophylaxis29.
Liver disorders : Isoniazid, rifampicin and
pyrazinamide are all potentially hepatotoxic. Of the
three, rifampicin is least likely to cause hepatocellular
damage. Patients with the following conditions can
receive the usual short-course chemotherapy regimens
provided there is no clinical evidence of chronic liver
disease - hepatitis virus carriage, past history of acute
hepatitis, excessive alcohol consumption. However,
in such patients hepatotoxic reactions to
antituberculosis therapy may be more common and
should therefore be anticipated. Patients with
established hepatic disease should not receive
pyrazinamide. Isoniazid plus rifampicin plus one or
two non-hepatotoxic drugs such as streptomycin and
ethambutol can be used for a total duration of 8
months. Alternate regimens are nine months of
rifampicin and ethambutol, or 12 months of
ethambutol and isoniazid with streptomycin for the
first two months29.
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If a patient with TB develops concurrent acute
hepatitis unrelated to TB or its treatment, and this
may be very difficult to distinguish, sometimes it
may be possible to defer TB treatment until the
acute hepatitis has resolved. In other cases, when
it is necessary to treat TB during acute hepatitis,
the combination of ethambutol and streptomycin
is the safest option. After the hepatitis resolves,
the patient can then receive a continuation phase
of six months of isoniazid and rifampicin. If the
hepat i t i s  has  not  resolved,  e thambutol  and
streptomycin should be continued for 12 months29.
Renal impairment :  Isoniazid, rifampicin and
pyrazinamide are either eliminated almost entirely
by biliary excretion or metabolized into non-toxic
compounds. These drugs can therefore be given
in  normal  dosages  to  pat ients  wi th  renal
impairment or failure. Patients with severe renal
failure should receive pyridoxine with isoniazid
to prevent peripheral neuropathy29.
Streptomycin and ethambutol are excreted by
the kidneys. These drugs can be given in reduced
doses if facilities are available for monitoring renal
function. Thioacetazone is partially excreted in the
urine;  however,  since the margin between a
therapeutic dose and a toxic dose is too narrow,
patients with renal failure should not receive this
drug. The safest regimen for patients with renal
failure is 6 months of isoniazid plus rifampicin
with pyrazinamide for the first 2 months29.
Tuberculosis with concomitant HIV infection: The
HIV epidemic has had an adverse impact on the
global epidemiology of TB with many parts of sub-
Saharan Africa and the Far East bearing the
brunt63. TB case rates have increased many times
in some countries solely attributed to HIV. It is
estimated that there were 3.82-4.58 million HIV
infected individuals in India as of December 200264,
with a majority of them also infected with TB and
thus being at greater risk of breaking down with
TB disease. The prevalence of HIV seropositivity
in TB patients varies widely across the country65-
67
. Current evidence suggests that anti-TB drug
resistance in HIV-TB patients is not yet a matter
of concern and the currently recommended 6-month
treatment for TB is expected to be as effective for
HIV infected TB patients as for HIV negative
ones67. However, this has not been established in a
clinical trial. Such a clinical trial is now in progress
in TRC, Chennai and the interim results should be
available in the near future. While TB patients with
concomitant HIV infection may respond as well to
standard antituberculosis treatment as those who
are immunocompetent, deaths during treatment,
partly due to HIV itself and partly due to other
HIV related diseases, are more frequent in HIV
infected patients, particularly in the advanced
stages of immunodeficiency. It is also likely that
relapses will be more in HIV-TB patients compared
to TB patients without HIV. Answers to these
questions are likely to become available from the
TRC cl inical  t r ia l .  Thioacetazone is
contraindicated in those who are HIV infected.
Highly active antiretroviral therapy (HAART)
is now recognized as the optimum treatment for
those in the later stages of HIV infection68.
Although HAART is now standard of care in the
industrialised countries, very few HIV-infected
people have access to HAART in places where the
burden of HIV is greatest (sub-Saharan Africa and
Asia). While HIV infection is now the biggest risk
factor for TB infection progressing to disease, TB
has also been shown to facilitate HIV replication
and dissemination through the dysregulation of
host cytokines, chemokines and their receptors69.
Thus the combination of antiretroviral treatment
along with antituberculosis treatment can be
expected to improve the outcome of patients with
TB and HIV.  While  consider ing t reatment
regimens for such patients it has to be remembered
that rifampicin cannot be used along with protease
inhibitors. In treating patients with HIV related TB,
the priority is to treat TB, especially smear-positive
pulmonary TB. Possible options for antiretroviral
therapy in TB patients include the following29.
( i)  Defer  ant i re t roviral  t reatment  t i l l  TB
treatment is completed; (ii) Defer antiretroviral
treatment until the end of the initial phase of
treatment for TB and use ethambutol and isoniazid
in the continuation phase; (iii) Treat TB with a
rifampicin-containing regimen and use efavirenz
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plus two nucleoside reverse transcriptase inhibitors
(NRTI); and (iv) Treat TB with a rifampicin-
containing regimen and use two NRTIs; then change
to a maximally suppressive HAART regimen on
completion of TB treatment.
Diabetes mellitus: Diabetes mellitus is a well-
recognized risk factor for TB. Preliminary results
from a clinical trial by the TRC, Chennai suggests
that the category 1 regimen of RNTCP (2EHRZ
thrice weekly/4HR thrice weekly) is sufficiently
effective for treating newly diagnosed smear-
positive pulmonary TB patients with concomitant
Type 2 diabetes mellitus, provided good glycemic
control is achieved (unpublished observation).
The present class of antituberculosis drugs was
introduced more than 30 yr ago. With the global
threat of TB in alliance with the HIV epidemic and
the spectre of multidrug resistant disease, there is
now a desperate need for new drugs to treat TB.
Medicines are needed which can both withstand the
test of resistance and ensure shorter treatment.
New methods such as combinatorial chemistry and
research breakthroughs such as  the genome
sequencing of M. tuberculosis70 have opened up
new avenues for the pursuit of novel compounds.
Possible drug targets could be gene products
involved in mycobacterial metabolism, persistence,
transcription, cell wall synthesis and virulence71.
Even with these initiatives it may be many years
before new drugs become available. The Global
Alliance for TB Drug Development plans to have
a new drug in production only by 201072. In the
interim, the window of opportunity offered by the
discovery of the antituberculosis activity of the
fluoroquinolones and the success of ofloxacin in a
clinical trial in patients has to be exploited.
Randomised clinical trials are being planned with
the newer generation fluoroquinolones such as
moxifloxacin and gatifloxacin to shorten treatment
duration.
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